{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:28:27Z","timestamp":1790155707175,"version":"4.0.1"},"reference-count":46,"publisher":"JLE","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.nephro.2016.02.003","type":"journal-article","created":{"date-parts":[[2016,3,8]],"date-time":"2016-03-08T23:59:15Z","timestamp":1457481555000},"page":"S105-S113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"S1","title":["Traitement de la maladie de Fabry\u00a0: succ\u00e8s, \u00e9checs, espoirs"],"prefix":"10.1684","volume":"12","author":[{"given":"Olivier","family":"Lidove","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Barbey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18929","reference":[{"key":"10.1016\/j.nephro.2016.02.003_bib0235","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1399-0004.2011.01718.x","article-title":"Fabry disease \u201cThe New Great Imposter\u201d: results of the French Observatoire in Internal Medicine Departments (FIMeD)","volume":"81","author":"Lidove","year":"2012","journal-title":"Clin Genet"},{"key":"10.1016\/j.nephro.2016.02.003_bib0240","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1750-1172-8-116","article-title":"Fibrosis: a key feature of Fabry disease with potential therapeutic implications","volume":"8","author":"Weidemann","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nephro.2016.02.003_bib0245","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/cge.12449","article-title":"Diagnostic dilemmas in Fabry disease: a case series study on GLA mutations of unknown clinical significance","volume":"88","author":"Smid","year":"2015","journal-title":"Clin Genet"},{"key":"10.1016\/j.nephro.2016.02.003_bib0250","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/glycob\/cwg034","article-title":"A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease","volume":"13","author":"Lee","year":"2003","journal-title":"Glycobiology"},{"key":"10.1016\/j.nephro.2016.02.003_bib0255","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1517\/14712598.4.7.1167","article-title":"Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval","volume":"4","author":"Desnick","year":"2004","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.nephro.2016.02.003_bib0260","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A phase 1\/2\u00a0clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies","volume":"68","author":"Eng","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.nephro.2016.02.003_bib0265","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A\u2013replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2016.02.003_bib0270","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilcox","year":"2004","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.nephro.2016.02.003_bib0275","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54\u00a0months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2016.02.003_bib0280","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1073\/pnas.97.1.365","article-title":"Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease","volume":"97","author":"Schiffmann","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nephro.2016.02.003_bib0285","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.nephro.2016.02.003_bib0290","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/mus.10497","article-title":"Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease","volume":"28","author":"Schiffmann","year":"2003","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nephro.2016.02.003_bib0295","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course","volume":"81","author":"Branton","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nephro.2016.02.003_bib0300","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006663.pub3","article-title":"Enzyme replacement therapy for Anderson-Fabry disease","volume":"2","author":"El Dib","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.nephro.2016.02.003_bib0305","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/GIM.0b013e3181f13b75","article-title":"Effects of enzyme replacement therapy in Fabry disease\u2013a comprehensive review of the medical literature","volume":"12","author":"Lidove","year":"2010","journal-title":"Genet Med"},{"key":"10.1016\/j.nephro.2016.02.003_bib0310","first-page":"77","article-title":"Enzyme replacement therapy and renal function in 201\u00a0patients with Fabry disease","volume":"66","author":"Schwarting","year":"2006","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nephro.2016.02.003_bib0315","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nephro.2016.02.003_bib0320","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","article-title":"Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease","volume":"52","author":"Germain","year":"2015","journal-title":"J Med Genet"},{"key":"10.1016\/j.nephro.2016.02.003_bib0325","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13023-015-0338-2","article-title":"Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10\u00a0years\u2019 treatment","volume":"10","author":"Kampmann","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nephro.2016.02.003_bib0330","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/GIM.0b013e3181a23bec","article-title":"A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36\u00a0women with Fabry disease","volume":"11","author":"Whybra","year":"2009","journal-title":"Genet Med"},{"key":"10.1016\/j.nephro.2016.02.003_bib0335","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/ndt\/gft452","article-title":"Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease","volume":"29","author":"Prabakaran","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2016.02.003_bib0340","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2012030316","article-title":"Agalsidase benefits renal histology in young patients with Fabry disease","volume":"24","author":"T\u00f8ndel","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2016.02.003_bib0345","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1681\/ASN.2008080870","article-title":"Agalsidase alfa and kidney dysfunction in Fabry disease","volume":"20","author":"West","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2016.02.003_bib0350","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/sj.ki.5000208","article-title":"Clinical benefit of enzyme replacement therapy in Fabry disease","volume":"69","author":"Breunig","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2016.02.003_bib0355","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s10545-015-9845-5","article-title":"A prospective 10-year study of individualized, intensified enzyme replacement therapy in advanced Fabry disease","volume":"38","author":"Schiffmann","year":"2015","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.nephro.2016.02.003_bib0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/8904_2014_371","article-title":"Innate and adaptive immune response in Fabry disease","volume":"22","author":"Mauhin","year":"2015","journal-title":"JIMD Rep"},{"key":"10.1016\/j.nephro.2016.02.003_bib0365","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1517\/13543784.11.10.1467","article-title":"Fabry disease: recent advances in enzyme replacement therapy","volume":"11","author":"Germain","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.nephro.2016.02.003_bib0370","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2016.02.003_bib0375","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jpeds.2007.09.007","article-title":"Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease","volume":"152","author":"Wraith","year":"2008","journal-title":"J Pediatr"},{"key":"10.1016\/j.nephro.2016.02.003_bib0380","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","article-title":"Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting","volume":"21","author":"Schiffmann","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2016.02.003_bib0385","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10545-005-4415-x","article-title":"Monitoring enzyme replacement therapy in Fabry disease\u2013role of urine globotriaosylceramide","volume":"28","author":"Whitfield","year":"2005","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.nephro.2016.02.003_bib0390","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","article-title":"Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry","volume":"11","author":"Waldek","year":"2009","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.nephro.2016.02.003_bib0395","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/ki.2013.520","article-title":"Establishing a biomarker for the vasculopathy of Fabry disease","volume":"86","author":"Shu","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2016.02.003_bib0400","first-page":"1","article-title":"Glycosphingolipid mediated caveolin-1\u00a0oligomerization","volume":"2","author":"Shu","year":"2012","journal-title":"J Glycomics Lipidomics"},{"key":"10.1016\/j.nephro.2016.02.003_bib0405","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/ki.2014.126","article-title":"3-Nitrotyrosine as a biomarker for vascular involvement in Fabry disease","volume":"86","author":"Joly","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2016.02.003_bib0410","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ymgme.2009.10.004","article-title":"Vasculopathy in patients with Fabry disease: current controversies and research directions","volume":"99","author":"Rombach","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nephro.2016.02.003_bib0415","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.coph.2013.01.006","article-title":"Uncoupling of endothelial NO synthase in atherosclerosis and vascular disease","volume":"13","author":"Li","year":"2013","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.nephro.2016.02.003_bib0420","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1136\/jmedgenet-2015-103471","article-title":"Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy","volume":"52","author":"Warnock","year":"2015","journal-title":"J Med Genet"},{"key":"10.1016\/j.nephro.2016.02.003_bib0425","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ymgme.2014.08.007","article-title":"Chronic kidney disease and an uncertain diagnosis of Fabry disease: approach to a correct diagnosis","volume":"114","author":"van der Tol","year":"2015","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nephro.2016.02.003_bib0430","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","article-title":"X-chromosome inactivation in female patients with Fabry disease","volume":"89","author":"Echevarria","year":"2016","journal-title":"Clin Genet"},{"key":"10.1016\/j.nephro.2016.02.003_bib0435","series-title":"Guide affection de longue dur\u00e9e. Maladie de Fabry. Protocole national de diagnostic et de soins","author":"Benistan","year":"2010"},{"key":"10.1016\/j.nephro.2016.02.003_bib0440","doi-asserted-by":"crossref","first-page":"e0124987","DOI":"10.1371\/journal.pone.0124987","article-title":"Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial","volume":"10","author":"Wijburg","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.nephro.2016.02.003_bib0445","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ymgme.2015.10.007","article-title":"The management and treatment of children with Fabry disease: a United States-based perspective","volume":"117","author":"Hopkin","year":"2016","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nephro.2016.02.003_bib0450","doi-asserted-by":"crossref","first-page":"e0134341","DOI":"10.1371\/journal.pone.0134341","article-title":"Oral migalastat HCl leads to greater systemic exposure and tissue levels of active \u03b1-galactosidase A in Fabry patients when co-administered with infused agalsidase","volume":"10","author":"Warnock","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.nephro.2016.02.003_bib0455","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2119\/molmed.2015.00088","article-title":"Efficacy of enzyme and substrate reduction therapy with a novel antagonist of glucosylceramide synthase for Fabry disease","volume":"21","author":"Ashe","year":"2015","journal-title":"Mol Med"},{"key":"10.1016\/j.nephro.2016.02.003_bib0230","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/ki.2014.432","article-title":"Rare inherited disorders with renal involvement-approach to the patient","volume":"87","author":"Joly","year":"2015","journal-title":"Kidney Int"}],"container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725516000341?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725516000341?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2016.02.003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T16:24:26Z","timestamp":1741191866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725516000341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":46,"alternative-id":["S1769725516000341"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2016.02.003","relation":{},"ISSN":["1769-7255"],"issn-type":[{"value":"1769-7255","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Traitement de la maladie de Fabry\u00a0: succ\u00e8s, \u00e9checs, espoirs","name":"articletitle","label":"Article Title"},{"value":"N\u00e9phrologie & Th\u00e9rapeutique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nephro.2016.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Association Soci\u00e9t\u00e9 de n\u00e9phrologie. Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}